Related Experiment Video
Updated: May 27, 2026
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
CD22 as a target for cancer therapy.
Xiao Tu1, Theresa LaVallee, Robert Lechleider
1MedImmune, LLC, One MedImmune Way, Gaithersburg, MD 20878, USA. tux@medimmune.com
Journal of Experimental Therapeutics & Oncology
|November 11, 2011
Summary
Novel immunotherapies targeting CD22 offer new hope for patients with relapsed or refractory B-cell malignancies. This review explores the potential of anti-CD22 agents in improving outcomes for these challenging hematological cancers.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Monoclonal antibodies like Rituximab have transformed hematological cancer treatment.
- A significant unmet need exists for effective therapies in relapsed/refractory B-cell malignancies.
- Targeting surface antigens on malignant B cells is a promising strategy.
Purpose of the Study:
- To review current knowledge on CD22 as a therapeutic target.
- To discuss the rationale for developing anti-CD22 immunotherapies.
- To highlight promising investigational anti-CD22 agents for B-cell malignancies.
Main Methods:
- Literature review of CD22 biology and therapeutic strategies.
- Analysis of the role of CD22 in B-cell malignancies.
- Summary of ongoing clinical investigations of anti-CD22 agents.
Main Results:
- CD22 is a B-cell-specific target with significant therapeutic potential.
- Several novel anti-CD22 agents are under development.
- These agents represent a promising alternative for patients with relapsed/refractory disease.
Conclusions:
- Targeting CD22 is a validated strategy for B-cell malignancies.
- Investigational anti-CD22 therapies show promise for improving patient outcomes.
- Further research and clinical trials are warranted to optimize CD22-directed treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...